EP Patent

EP2992903A1 — Combination of a naloxol-peg conjugate and an opioid agonist

Assigned to AstraZeneca AB · Expires 2016-03-09 · 10y expired

What this patent protects

Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phoshate salt forms including crystalline forms. To achieve a central analgesic effect, the conjugates will be administered an opioid agonist.

USPTO Abstract

Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phoshate salt forms including crystalline forms. To achieve a central analgesic effect, the conjugates will be administered an opioid agonist.

Drugs covered by this patent

naloxegol-oxalate (NALOXEGOL OXALATE)

Patent Metadata

Patent number: EP2992903A1
Jurisdiction: EP
Classification: —
Expires: 2016-03-09
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.